the use of high-dose Advair for COPD

April 2007

Glaxo will promote the use of high-dose Advair for COPD.

This is based on a new study comparing the combination of fluticasone and salmeterol (Advair) to salmeterol alone (Serevent).

It shows that high-dose Advair is better than Serevent in reducing exacerbations and the need for systemic steroids.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote